FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.
http://ift.tt/2xA9NWq
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου